Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin

Diabetes Research and Clinical Practice

Volumn 108, Issue 3, 2015, Pages e67-e70

  Wang, Man Man ^a   Lin, Shuo ^a   Chen, Yan Ming ^a   Shu, Jiong ^a   Lu, Hong Yun ^b   Zhang, Yong Jun ^b   Xie, Ru Ying ^a   Zeng, Long Yi ^a   Mu, Pan Wei ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acarbose; Glycaemic variability; Saxagliptin; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ACARBOSE; ADAMANTANE; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84930180752     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.02.022     Document Type: Article

References (20)

1. Ceriello A., Ihnat M.A. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 2010, 27:862-867.
2. Monnier L., Colette C., Owens D.R. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?. J Diabetes Sci Technol 2008, 2:1094-1100.
3. Wang J.S., Lin S.D., Lee W.J., Su S.L., Lee I.T., Tu S.T., et al. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2011, 33:1932-1942.
4. Kusunoki Y., Katsuno T., Myojin M., Miyakoshi K., Ikawa T., Matsuo T., et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J 2013, 60:431-439.
5. International Diabetes Federation Guideline Development Group Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014, 104(1):1-52.
6. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000, 23:45-50.
7. Mellbin L.G., Malmberg K., Ryden L., Wedel H., Vestberg D., Lind M. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial. Eur Heart J 2013, 34:374-379.
8. Piconi L., Quagliaro L., Da R.R., Assaloni R., Giugliano D., Esposito K., et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004, 2:1453-1459.
9. Quagliaro L., Piconi L., Assaloni R., Da R.R., Maier A., Zuodar G., et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005, 183:259-267.
10. Sun J., Xu Y., Sun S., Sun Y., Wang X. Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: the role of mitochondrial reactive oxygen species. Mol Cell Biochem 2010, 343:27-35.
11. Shimabukuro M., Higa N., Chinen I., Yamakawa K., Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006, 91:837-842.
12. Sjostrand M., Iqbal N., Lu J., Hirshberg B. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract 2014, 105:185-191.
13. Fischer S., Patzak A., Rietzsch H., Schwanebeck U., Kohler C., Wildbrett J., et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab 2003, 5:38-44.
14. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
15. Goke B., Gallwitz B., Eriksson J., Hellqvist A., Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010, 64:1619-1631.
16. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
17. Mu J., Petrov A., Eiermann G.J., Woods J., Zhou Y.P., Li Z., et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009, 623:148-154.
18. Kania D.S., Gonzalvo J.D., Weber Z.A. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther 2011, 33:1005-1022.
19. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de Lisdonk E.H., Rutten G.E., Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, D3639.
20. Shimoda S., Iwashita S., Ichimori S., Matsuo Y., Goto R., Maeda T., et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J 2013, 60:1207-1214.